Haystack Oncology
- Company typePrivate
- Founded2021
- HeadquartersBaltimore, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
Haystack Oncology firmographics
Firmographics- Name
- Haystack Oncology
- Legal name
- Haystack Oncology Inc.
- Website
- https://haystackoncology.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Haystack Oncology industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)
- akta.pro secondary industries
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Haystack Oncology is headquartered
LocationHeadquarters
- HQ city
- Baltimore
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Haystack Oncology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- ctDNA MRD diagnostic testing: Haystack MRD is offered as a laboratory-developed test under CLIA regulations, sold to clinicians who order it for cancer patients. Revenue is generated per test performed. As a Quest Diagnostics subsidiary, the test is delivered through Quest's nationwide lab network, enabling broad access and scaling.
- Technology licensing (Europe): Haystack Oncology licenses its MRD technology to international partners such as MVZ HPH in Germany, enabling localized testing delivery in Europe. This generates licensing revenue while expanding global patient access.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Haystack Oncology product offering
Product offeringCore offering
Haystack Oncology develops and commercializes Haystack MRD®, a tumor-informed minimal residual disease (MRD) liquid biopsy test that detects circulating tumor DNA (ctDNA) in blood using proprietary dual-strand error-correction technology with a limit of detection of 0.0006%. The test is offered as a CLIA-regulated laboratory-developed test to oncologists for residual disease detection, neoadjuvant response assessment, treatment response monitoring, and recurrence surveillance across solid tumor cancers, and is also supplied to biopharma companies for clinical trial applications. The service is delivered exclusively through parent company Quest Diagnostics' nationwide laboratory network and internationally via technology licensing agreements.
Product overview
Haystack Oncology offers a single unified product: Haystack MRD®, a tumor-informed minimal residual disease (MRD) test that detects circulating tumor DNA (ctDNA) through liquid biopsy. The test uses proprietary dual-strand error-correction technology for exceptional sensitivity and specificity, enabling clinicians to detect residual or recurring disease in solid tumor cancer patients earlier than traditional imaging methods. The technology was developed by cancer genomics pioneers and further developed by parent company Quest Diagnostics. A European version called HPH MRD is available through a licensing agreement with MVZ HPH in Germany. The initial product was branded as Haystack Duo™ but has since been rebranded as Haystack MRD®.
Differentiator
Problem solved
Functional benefit
Products and services
- Haystack MRD® A tumor-informed minimal residual disease (MRD) liquid biopsy test that detects circulating tumor DNA (ctDNA) in blood using proprietary dual-strand error-correction technology, with a limit of detection of 0.0006%. Sold to oncologists for neoadjuvant response assessment, residual disease detection, adjuvant therapy decision-making, treatment response monitoring, and recurrence surveillance in solid tumor cancer patients (breast, colorectal, ovarian, prostate, and others); also supplied to biopharma companies for clinical trial applications.
- HPH MRD A tumor-informed circulating tumor DNA blood test for detecting minimal residual disease in solid tumor cancer patients, launched in Europe through a licensing agreement with Haystack Oncology. Operated by MVZ HPH in Hamburg, Germany using Haystack's whole-genome sequencing technology and personalized panel design to enable localized European testing access.
Quantifiable outcome
- ctDNA testing using Haystack MRD identified clinical complete response at a median of 1.4 months compared to over 6 months for traditional imaging
- +2 more outcomes
Companies that use Haystack Oncology
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Haystack Oncology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Haystack Oncology partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major and regional.
- City of HopemajorCity of Hope, one of the largest U.S. cancer research and treatment organizations, is implementing Haystack MRD in a multi-year clinical research program enrolling ~500 patients across 14 sites in major U.S. metropolitan areas. The program evaluates MRD detection, treatment response monitoring, and recurrence identification in breast, colorectal, ovarian, and prostate cancers.
- MVZ HPH Institute for Pathology and HematopathologyregionalMVZ HPH in Hamburg, Germany licensed Haystack MRD technology to launch HPH MRD, a tumor-informed ctDNA blood test for detecting minimal residual disease in solid tumor cancer patients in Europe. The licensing agreement enables localized testing at HPH's Hamburg laboratories using Haystack's whole-genome sequencing technology, addressing a gap in European access to advanced MRD testing.
- Memorial Sloan Kettering Cancer CentermajorMemorial Sloan Kettering Cancer Center led the landmark clinical study validating Haystack MRD's clinical utility. The study, published in the New England Journal of Medicine in May 2025, demonstrated that ctDNA testing using Haystack MRD identified clinical complete response at a median of 1.4 months compared to over 6 months for traditional imaging, establishing the test's clinical evidence base.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Haystack Oncology competitors and assessment
Company assessmentMarket position
Weaknesses1 record
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Haystack Oncology social profiles
Digital presenceHaystack Oncology compliance and trust
Trust signalCompliance2 records
Haystack Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Haystack Oncology leadership team
Management profileNumber of profiles
Profiles5 records
Haystack Oncology funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Haystack Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Haystack Oncology
What does Haystack Oncology do?
Haystack Oncology develops and commercializes Haystack MRD®, a tumor-informed minimal residual disease (MRD) liquid biopsy test that detects circulating tumor DNA (ctDNA) in blood using proprietary dual-strand error-correction technology with a limit of detection of 0.0006%. The test is offered as a CLIA-regulated laboratory-developed test to oncologists for residual disease detection, neoadjuvant response assessment, treatment response monitoring, and recurrence surveillance across solid tumor cancers, and is also supplied to biopharma companies for clinical trial applications. The service is delivered exclusively through parent company Quest Diagnostics' nationwide laboratory network and internationally via technology licensing agreements.
Is Haystack Oncology a public or private company?
Haystack Oncology is a private company. It is classified as corporate owned and is currently operating.
When was Haystack Oncology founded?
Haystack Oncology was founded in 2021. It employs 51 to 100 people.
Where is Haystack Oncology based?
Haystack Oncology is headquartered in Baltimore, United States, in the North America region.
How does Haystack Oncology make money?
Two revenue lines are on record. ctDNA MRD diagnostic testing is the primary driver. The others are technology licensing (Europe).
Does Haystack Oncology have an API?
No public API is recorded for Haystack Oncology.
What industry is Haystack Oncology in?
Haystack Oncology's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 2835.